The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 100%. Our forward projection puts the odds of a 10% gain over the next month near 3%.
22nd Century Group Inc
XXII · NASDAQ · USD · Market cap $2M · 32 employees
22nd Century Group, Inc., a tobacco products company, manufactures, distributes, and sells proprietary new reduced nicotine tobacco products in the United States.
FAIL · Does not pass the screenAt the last full screen
2026-06-14
Screened 2026-06-14 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
This name holds its distribution label.
22nd Century Group Inc holds its Distribution at $6.55. Elevated stress, defensive posture warranted, held for 23 days.
| Phase | Distribution · caution |
| Quantitative state | Elevated stress, defensive posture warranted, held for 23 days |
| Price at the screen | $6.55 |
| Valuation | N/A trailing · -0.43 forward price to earnings |
| Values screen | FAIL · score 30.0 |
| Beta | 0.60 |
Five Screens, Shown in Full
Does not pass. Excluded industry: Tobacco
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Excluded industry: Tobacco | Fail |
| Debt load | Excluded | Below 33% | Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | Excluded | Below 33% | Interest-bearing cash and securities are of assets, above the one-third limit. | Fail |
| Receivables | Excluded | Below 49% | Money owed to the company is of assets, above the 49% limit. | Fail |
| Revenue purity | Excluded | Below 5% | of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Business, in Plain Words| Forward P/E | -0.4x |
| EPS, trailing | -650.73 |
| EPS, forward | -15.26 |
| Revenue growth | -43.3%revenue is shrinking |
| Profit margin | -65.8%currently unprofitable |
| Return on equity | -103.6%not currently earning a positive return on equity |
| Debt to equity | 0.06minimal debt: a conservative balance sheet |
| Beta | 0.60steadier than the market |
| 52-week range | 5.42 - 4,485.00 |
| Moat | NONE |
| Market cap | $2M |
| Employees | 32 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeXXII trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 100%. Our forward projection puts the odds of a 10% gain over the next month near 3%.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $0.59 | -43.8% | · | $562 | -43.8% |
| 2 months | $2.01 | -83.4% | · | $166 | -83.4% |
| 3 months | $3.70 | -91.0% | · | $90 | -91.0% |
| 6 months | $17.10 | -98.1% | · | $20 | -98.1% |
| 1 year | $248.40 | -99.9% | · | $1 | -99.9% |
| 2 years | $32,835.38 | -100.0% | · | $0 | -100.0% |
| 3 years | $6,472,062.00 | -100.0% | · | $0 | -100.0% |
| 5 years | $53,542,620.00 | -100.0% | · | $0 | -100.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever XXII does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.